Suppr超能文献

帕金森病与肠道微生物群的联系:揭示生态失调并探索治疗前景。

Parkinson's disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons.

作者信息

Yadav Satyam, Raj Rojin G

机构信息

Department of Pharmacy Practice, ISF College of Pharmacy (An Autonomous College), Moga, Punjab 142001, India.

Department of Pharmacy Practice, ISF College of Pharmacy (An Autonomous College), Moga, Punjab 142001, India.

出版信息

Neuroscience. 2025 Aug 16;581:1-15. doi: 10.1016/j.neuroscience.2025.07.003. Epub 2025 Jul 2.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuronal loss, α-synuclein aggregation, and sustained neuroinflammation. Emerging evidence supports the gut-brain-microbiota axis as a pivotal player in the disease's pathogenesis. Dysbiosis, disruptions in the gut microbial composition, has been consistently observed in individuals with PD, with notable reductions in beneficial, short-chain fatty acid-producing bacteria and elevations in pro-inflammatory microbial species. These alterations contribute to increased intestinal permeability, systemic inflammation, and heightened neuroinflammatory responses that may drive α-synuclein misfolding and dopaminergic degeneration. In addition, microbial metabolites, including lipopolysaccharides and amyloid proteins such as curli, may promote neurodegeneration via immune and molecular mimicry pathways. Recent advances highlight the bidirectional influence of the microbiota-gut-brain axis on PD symptoms, ranging from motor deficits to non-motor features like constipation, depression, and cognitive decline. Several microbiota-modulating interventions, including probiotics, prebiotics, dietary strategies, antibiotics, and fecal microbiota transplantation, have demonstrated neuroprotective potential in both preclinical and clinical contexts. However, inter-individual variability, methodological heterogeneity, and the absence of longitudinal, multi-omics-integrated studies limit current understanding. The gut microbiome also holds promise as a non-invasive biomarker for early PD detection and prognosis, though standardization remains a challenge. Future research must clarify causal mechanisms, optimize therapeutic delivery, and integrate genetic, metabolic, and environmental data to advance precision medicine approaches. This review consolidates current knowledge on gut microbiota's role in PD pathophysiology and therapeutic innovation, providing a roadmap for future research directions.

摘要

帕金森病(PD)是一种进行性神经退行性疾病,其特征为多巴胺能神经元丧失、α-突触核蛋白聚集和持续性神经炎症。新出现的证据支持肠-脑-微生物群轴在该疾病发病机制中起关键作用。在帕金森病患者中一直观察到肠道微生物群失调,即肠道微生物组成的破坏,有益的产短链脂肪酸细菌显著减少,促炎微生物种类增加。这些改变导致肠道通透性增加、全身炎症和神经炎症反应加剧,可能促使α-突触核蛋白错误折叠和多巴胺能神经元变性。此外,包括脂多糖和卷曲菌毛等淀粉样蛋白在内的微生物代谢产物,可能通过免疫和分子模拟途径促进神经退行性变。最近的进展突出了微生物群-肠-脑轴对帕金森病症状的双向影响,范围从运动功能障碍到便秘、抑郁和认知衰退等非运动特征。包括益生菌、益生元、饮食策略、抗生素和粪便微生物群移植在内的几种调节微生物群的干预措施,在临床前和临床环境中均已显示出神经保护潜力。然而,个体间差异、方法学异质性以及缺乏纵向的多组学综合研究限制了目前的认识。尽管标准化仍然是一个挑战,但肠道微生物群作为帕金森病早期检测和预后的非侵入性生物标志物也具有前景。未来的研究必须阐明因果机制,优化治疗方法,并整合遗传、代谢和环境数据,以推进精准医学方法。本综述整合了关于肠道微生物群在帕金森病病理生理学和治疗创新中作用的现有知识,为未来的研究方向提供了路线图。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验